Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 96
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Reanimation ; 24(Suppl 2): 379-385, 2015.
Artículo en Francés | MEDLINE | ID: mdl-32288742

RESUMEN

In the last decade, we faced a large number of emerging pathogens. As a consequence we had to adapt our medical practice as well as our health system. This review summarizes the main features of the recent emerging pathogens with a particular focus on the recent and ongoing Ebola outbreak, we tried to evaluate the consequences on our national health management.

3.
4.
Euro Surveill ; 18(24)2013 Jun 13.
Artículo en Inglés | MEDLINE | ID: mdl-23787161

RESUMEN

In May 2013, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection was diagnosed in an adult male in France with severe respiratory illness, who had travelled to the United Arab Emirates before symptom onset. Contact tracing identified a secondary case in a patient hospitalised in the same hospital room. No other cases of MERS-CoV infection were identified among the index case's 123 contacts, nor among 39 contacts of the secondary case, during the 10-day follow-up period.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Viaje , Trazado de Contacto , Coronavirus/aislamiento & purificación , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/transmisión , Transmisión de Enfermedad Infecciosa/prevención & control , Resultado Fatal , Francia , Humanos , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/prevención & control , Infecciones del Sistema Respiratorio/transmisión , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Emiratos Árabes Unidos
5.
Eur J Clin Microbiol Infect Dis ; 31(11): 2929-33, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22644056

RESUMEN

Blood cultures from outpatients receiving home parenteral nutrition (HPN) via long-term central venous access (CVA) were retrospectively analyzed from January 2003 to May 2009. When infection of the CVA was not due to Staphylococcus aureus, Pseudomonas aeruginosa, or Candida, catheter salvage was attempted for a maximum of three consecutive infections on the same CVA. Factors influencing the time-to-next-infection were studied, whether the catheter was changed after the last infection or not. Neither the McCabe score, age, history of cancer, diabetes mellitus nor immunosuppression, curative antibiotic lock, type of bacteria, type or duration of treatment had an influence on the time-to-next-infection. The time-to-next-infection was significantly associated with the status of CVA (saved or changed) and its type (tunneled catheter with or without a cuff, or implanted port catheter).


Asunto(s)
Infecciones Relacionadas con Catéteres/epidemiología , Nutrición Parenteral en el Domicilio/efectos adversos , Sepsis/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Infecciones Relacionadas con Catéteres/microbiología , Humanos , Persona de Mediana Edad , Recurrencia , Estudios Retrospectivos , Factores de Riesgo , Sepsis/microbiología , Factores de Tiempo
6.
Infect Dis Now ; 52(5): 267-272, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35537689

RESUMEN

OBJECTIVES: Clostridioides difficile infection (CDI) is a disease with high morbidity and mortality rates. The objective of this study was to describe CDI epidemiology and patient characteristics over a 5-year period in Switzerland and assess risk factors for mortality, recurrence and severe CDI. PATIENTS AND METHODS: We retrospectively included all consecutive CDI cases having occurred in adult patients hospitalized in two tertiary centers: the Lausanne University Hospital (1000 beds) and the University Hospital of Zurich (900 beds), between 2014 and 2018. Suspected cases of CDI were identified from the microbiology laboratory database on the basis of a positive test and confirmed by records review. RESULTS: During first CDI episodes, the median age was 67 years and the median Charlson comorbidity index (CCI) score was 5. All in all, 299 out of 826 patients (36.2%) had severe infection based on the Infectious Diseases Society of America criteria. In the multivariable analysis, CCI was associated with increased risk of mortality. None of the factors recorded on admission were significantly associated with increased risk of recurrence. In the multivariable analysis, male sex and CCI were associated with severity, while immunosuppression was associated with less severe presentation. CONCLUSIONS: If we did not identify any criteria on admission that could be predictive of recurrences, this could be explained the retrospective nature of the study. A higher comorbidity index is a key driver for severe CDI and mortality. Reporting of CDI is not mandatory in Switzerland; structuration of CDI reporting should be a short-term priority.


Asunto(s)
Clostridioides difficile , Infecciones por Clostridium , Adulto , Anciano , Infecciones por Clostridium/epidemiología , Infecciones por Clostridium/microbiología , Humanos , Masculino , Estudios Retrospectivos , Factores de Riesgo , Suiza/epidemiología
7.
Exp Lung Res ; 35(4): 263-71, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19415544

RESUMEN

Transvascular transport of labeled-albumin is used to study endothelial permeability in experimental murine models of pulmonary infections. But radio-tagged albumin necessitates heavy safety procedures in terms of storage, manipulation and evacuation. The authors tested fluorescein isothiocyanate-tagged albumin (FITC-albumin) as a new marker for determination of endothelial permeability in a murine model of lung infection by Pseudomonas aeruginosa PAO1, in comparison with a standard method with (125)I-albumin. The mean permeability +/- SEM measured with (125)I-albumin was 2.45%/2 h +/- 0.37 for the control mice and 6.65%/2 h +/- 0.77 for the infected ones (P < .0001). With FITC-albumin, results obtained for both groups were respectively 4.96%/2 h +/- 0.64 and 11.5%/2 h +/- 1.2 (P < .0001). Spearman's rank coefficient was equal to .88 (P < .0001), showing a very strong correlation between both methods of measurement. The Bland-Altman analysis of bias revealed that there was no significant bias between FITC-albumin-derived and (125)I-albumin-derived values. The correction of the values obtained in plasma and lung homogenate supernatants by the subtraction of natural spontaneous fluorescence measured in these samples was crucial for the calculation of endothelial permeability in this new method. We believe that FITC-albumin can be useful for assessment of endothelial permeability in murine models of pulmonary diseases.


Asunto(s)
Permeabilidad Capilar , Endotelio Vascular/metabolismo , Fluoresceína-5-Isotiocianato/análogos & derivados , Albúmina Sérica , Animales , Fluoresceína-5-Isotiocianato/farmacocinética , Radioisótopos de Yodo/farmacocinética , Métodos , Ratones , Pseudomonas aeruginosa , Reproducibilidad de los Resultados , Infecciones del Sistema Respiratorio/diagnóstico , Infecciones del Sistema Respiratorio/patología , Albúmina Sérica/farmacocinética
8.
Med Mal Infect ; 39(5): 330-40, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19304423

RESUMEN

UNLABELLED: Studies have shown similar clinical cure rates and shorter length of hospitalization when using linezolid compared to vancomycin in patients with complicated skin and soft-tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). OBJECTIVE: This study had for aim to compare the cost-effectiveness of linezolid versus vancomycin in French healthcare settings. METHOD: A decision-analytic model followed an average patient from the initiation of an empiric treatment until cure, death or second-line treatment failure. A clinical data probability was obtained from clinical trials, resource utilization data (including treatment duration and length of hospitalization) and prevalence of MRSA was obtained from a Delphi panel, and costs from published sources. RESULTS: First-line cure rate for linezolid-treated patients was 90.7% versus 85.5% for vancomycin; the total cure rates after two lines of treatment were 98.5% and 98.0%, respectively. The average total cost was 7,778euro for linezolid versus 8,777euro for vancomycin. The mean estimated length of hospitalization after two lines of treatment was 10.7 days for linezolid versus 13.3 days for vancomycin. The increased effectiveness and reduced cost lead to more frequent prescription. This did not change after one-way sensitivity analyses. CONCLUSION: Linezolid may be considered as a cost-effective treatment for patients with complicated skin and soft-tissue infections suspected to be MRSA related in France.


Asunto(s)
Acetamidas/uso terapéutico , Antiinfecciosos/uso terapéutico , Staphylococcus aureus Resistente a Meticilina , Oxazolidinonas/uso terapéutico , Enfermedades Cutáneas Infecciosas/tratamiento farmacológico , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Acetamidas/economía , Antibacterianos/economía , Antibacterianos/uso terapéutico , Antiinfecciosos/economía , Árboles de Decisión , Monitoreo de Drogas/métodos , Monitoreo de Drogas/normas , Francia , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/economía , Humanos , Pacientes Internos , Linezolid , Oxazolidinonas/economía , Infecciones Estafilocócicas/economía , Infecciones Cutáneas Estafilocócicas/economía
9.
Clin Microbiol Infect ; 14(4): 337-43, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18190582

RESUMEN

Respiratory isolates of Pseudomonas aeruginosa were collected from 58 critically-ill patients with ventilator-associated pneumonia. Expression of elastase and pyocyanin was assessed semi-quantitatively, while quorum-sensing activity was assessed by quantifying the levels of the autoinducers N-3-oxododecanoyl-L-homoserine lactone (C12-HSL) and N-butanoyl-L-homoserine lactone (C4-HSL). Correlations were sought between quorum-sensing activity and the expression of these two virulence factors, and all results were compared to those obtained with the laboratory reference strains PA103, a strain defective in quorum-sensing, and PAO1, a functional quorum-sensing strain. More than two-thirds of clinically pathogenic isolates had increased levels of elastase and/or pyocyanin, and high quorum-sensing activity, as assessed by autoinducer levels. However, a strong correlation between quorum-sensing activity and virulence factor production was revealed only for elastase and not for pyocyanin (C12-HSL/elastase, r = 0.7, p 2 x 10(-9); C4-HSL/elastase, r = 0.7, p 2 x 10(-9)). These data suggest that the pathogenicity of P. aeruginosa isolates from critically-ill patients with ventilator-associated pneumonia is caused, at least in part, by an increase in elastase production regulated by quorum-sensing, while increased pyocyanin production in these isolates may be regulated predominantly by mechanisms other than quorum-sensing.


Asunto(s)
Regulación Bacteriana de la Expresión Génica , Neumonía Asociada al Ventilador/microbiología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/patogenicidad , Percepción de Quorum , Factores de Virulencia/metabolismo , 4-Butirolactona/análogos & derivados , 4-Butirolactona/metabolismo , Proteínas Bacterianas , Humanos , Elastasa Pancreática/genética , Elastasa Pancreática/metabolismo , Pseudomonas aeruginosa/crecimiento & desarrollo , Pseudomonas aeruginosa/aislamiento & purificación , Piocianina/genética , Piocianina/metabolismo , Factores de Virulencia/genética
10.
Arch Pediatr ; 15(12): 1781-93, 2008 Dec.
Artículo en Francés | MEDLINE | ID: mdl-18995996

RESUMEN

The influenza pandemic will create a major increase in demand for hospital admissions, particularly for critical care services. The recommendations detailed herein have been elaborated by experts from medical societies potentially involved in this situation and focus on general hospital organization. Intensive care units will initially face high demand for admission; the Healthcare Authorities must therefore study how ICU capacity can be expanded. Pediatric intensive care units will be particularly affected by this situation of relative bed shortage, since young children, particularly infants, are expected to be affected by severe clinical forms of avian flu. Therefore, the weight threshold for admission to the adult ICU was lowered to 20 kg. Neonatal intensive care units (NICU) should remain, if possible, low viral density areas. Mixed (neonatal and pediatric) intensive care units could be dedicated to infants and children only. NICU admission of extreme premature babies should be limited in this difficult situation. Pediatric intensive care units (PICU) admission capacity could be doubled by using intermediate care and postoperative care units. The staff could be increased by doctors and nurses involved in canceled programmed activities. Healthcare workers transferred to PICU should be given special training.


Asunto(s)
Brotes de Enfermedades , Hospitales Generales/organización & administración , Subtipo H5N1 del Virus de la Influenza A , Gripe Aviar/transmisión , Gripe Humana/epidemiología , Unidades de Cuidado Intensivo Neonatal/organización & administración , Unidades de Cuidado Intensivo Pediátrico/organización & administración , Adolescente , Adulto , Animales , Aves , Niño , Preescolar , Francia/epidemiología , Humanos , Lactante , Recién Nacido , Triaje , Recursos Humanos
11.
Rev Mal Respir ; 25(2): 223-35, 2008 Feb.
Artículo en Francés | MEDLINE | ID: mdl-18449083

RESUMEN

The development of an epidemic of avian influenza will have a major impact on the organisation and structure of the facilities for treatment. This paper, the product of collaboration between the six learned societies concerned, analyses the impact of a possible pandemic on the various aspects of management of patients requiring intensive care. It describes the organisation of hospital pathways for flu and non-flu patients with, in particular, the necessary actions in terms of separation of care facilities, the triage of patients and the cancellation of non-urgent activities. It analyses the preconditions necessary for the efficient functioning of intensive care and the predictable limiting factors. It underlines the importance of training of medical and paramedical personnel. Finally, it tackles the specific problems of paediatric intensive care: organisation, capacity for admissions and training.


Asunto(s)
Cuidados Críticos/organización & administración , Brotes de Enfermedades/prevención & control , Gripe Aviar/prevención & control , Animales , Aves , Humanos , Triaje/organización & administración
12.
Med Mal Infect ; 38(6): 318-23, 2008 Jun.
Artículo en Francés | MEDLINE | ID: mdl-18455339

RESUMEN

UNLABELLED: Pseudomonas aeruginosa is a Gram-negative bacillus frequently encountered in human diseases. P. aeruginosa produces a large number of secreted and cell associated virulence factors. Their production is coordinated by various systems of gene regulation. The correlation and sequential intervention of regulation systems during a pulmonary infection have not been determined yet. OBJECTIVE: The aim of this study was to analyze the expression of three P. aeruginosa virulence genes (exoS, lasI, and algD) during the first seven days of chronic lung infection. To do so, mice were infected intratracheally with agarose beads containing P. aeruginosa. RESULTS: The results were a progressive decrease of exoS transcription and an increase of algD, and lasI transcription during infection. This dynamic evolution was consistent with the clinical observation, which demonstrated a progressive loss of type III secretion system function and an increase in the mucoid phenotype development in P. aeruginosa strains from cystic fibrosis patients. CONCLUSION: The development of a P. aeruginosa pulmonary chronic infection associates a decrease of gene expression related to a type III secretion system and an increase of alginate production.


Asunto(s)
Infecciones por Pseudomonas/fisiopatología , Pseudomonas aeruginosa/genética , Pseudomonas aeruginosa/patogenicidad , Virulencia/genética , Animales , Cartilla de ADN , Modelos Animales de Enfermedad , Regulación Bacteriana de la Expresión Génica , Ratones , Pseudomonas aeruginosa/aislamiento & purificación , Transcripción Genética
13.
Med Mal Infect ; 48(1): 10-17, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29336930

RESUMEN

Clostridium difficile is an anaerobic spore-forming Gram-positive bacillus recognized as an evolving international health problem. Metronidazole and vancomycin were - until recently - the only drugs available to treat C. difficile infection (CDI). Better knowledge of the pathophysiology and the development of new drugs completely modified the management of initial episodes and recurrences of CDI. Fidaxomicin significantly reduced recurrences compared with vancomycin. New drugs are also currently evaluated (cadazolid, surotomycin, ridinilazole, rifaximin). Gut microbiota homeostasis was clearly shown to be a key determinant in recurrences as demonstrated by the development of gut microbiota transplantation and alternative microbiota substitution. Passive immunotherapy and vaccinal approaches are also currently being evaluated. In conclusion, CDI treatment has evolved with the development of new therapeutic pathways which now need to be implemented in international guidelines.


Asunto(s)
Infecciones por Clostridium/terapia , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Vacunas Bacterianas , Clostridioides difficile/efectos de los fármacos , Infecciones por Clostridium/tratamiento farmacológico , Infecciones por Clostridium/microbiología , Infecciones por Clostridium/prevención & control , Trasplante de Microbiota Fecal , Microbioma Gastrointestinal , Humanos , Inmunización Pasiva , Recurrencia , Terapias en Investigación , Resultado del Tratamiento , Vacunas Sintéticas
14.
Med Mal Infect ; 48(2): 103-113, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29191391

RESUMEN

OBJECTIVES: Streptococcus pneumoniae is the leading cause of community-acquired pneumonia. We aimed to analyze the epithelial response to S. pneumoniae-induced lung injury. METHODS: Using an in vitro model with 16HBE cells and experimental in vivo murine model of acute lung injury, we analyzed the epithelial response to S. pneumoniae. Lung epithelial cell monolayers were exposed to S. pneumoniae and permeability was assessed by transepithelial resistance (TER) measurement and organization and expression of junction proteins. Functional consequences were studied with an in vivo murine model measuring alveolar permeability, distal alveolar fluid clearance (DAFC), and the alveolar inflammatory response. RESULTS: In vitro, S. pneumoniae induced a dose-dependent decrease in transepithelial resistance, which was associated with significant modifications in the organization of junction proteins assessed by immunofluorescence staining and expression after 6hours of exposure. In vivo, S. pneumoniae induced a transient increase in alveolar permeability with an adequate increase in DAFC 6hours post infection. In a second phase, a permanent increased permeability was associated with a major decrease in DAFC. CONCLUSION: Overall, the epithelial response to S. pneumoniae followed a biphasic pattern with an initial reversible increase in permeability related to the alteration of tight and adherens junctions and a second phase associated with an epithelial injury with a major increase in permeability with a decreased DAFC reflecting an injured alveolar capillary barrier.


Asunto(s)
Lesión Pulmonar Aguda/microbiología , Neumonía Neumocócica/complicaciones , Animales , Modelos Animales de Enfermedad , Femenino , Ratones , Ratones Endogámicos C57BL
15.
Med Mal Infect ; 37(6): 354-6, 2007 Jun.
Artículo en Francés | MEDLINE | ID: mdl-17303362

RESUMEN

Pneumonia with septicemia caused by Pasteurella multocida was diagnosed in an immunocompetent patient exposed to a dog. This case is remarkable by two aspects: first the absence of visible cutaneous lesion, and second the localization and severity of the infection caused by P. multocida even though the patient was immunocompetent. P. multocida can cause respiratory and systemic infection, and it is a possible diagnosis in case of exposure to animals, even without history of bite or scratch. Furthermore, severe infections caused by this pathogen can occur in immunocompetent patients, so that the implication of specific host factors in the severity of the disease can be suspected. Genetic features could be one of these.


Asunto(s)
Perros/microbiología , Infecciones por Pasteurella/complicaciones , Pasteurella multocida , Sepsis/microbiología , Animales , Humanos , Inmunocompetencia , Masculino
16.
Med Mal Infect ; 47(8): 532-539, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28823390

RESUMEN

OBJECTIVES: Adults with hematological malignancies are at high-risk of Clostridium difficile infection (CDI), but no guidelines for CDI treatment are available in this population. Our primary objective was to evaluate the clinical outcomes in CDI patients with hematological malignancies. Our secondary objectives were to describe CDI severity using the main clinical guidelines and to evaluate the compliance of treatment choice with published guidelines. PATIENTS AND METHODS: Single-center, retrospective, observational case series including every consecutive adult patient with a confirmed diagnosis of CDI admitted in the hematology unit of our teaching hospital. Each CDI episode was classified as moderate, severe, or complicated according to the main clinical guidelines (IDSA 2010, AJG 2013, ESCMID 2014). RESULTS: Twenty-three episodes of CDI in 19 patients admitted to the hematology unit occurred between June 2012 and October 2013. Clinical cure was achieved for 20 episodes (87%). Ten weeks after diagnosis, global cure was reached for 14 episodes (61%) whereas recurrence occurred in two episodes (10%). The mortality rate reached 37% (7/19) but the attributable mortality rate was 5% (1/19). ESCMID criteria more frequently classified patients in the severe category compared with the two other classifications. Prescription compliance with clinical guidelines was observed in 61% of episodes with IDSA criteria, 43% with AJG, and 9% with ESCMID. CONCLUSIONS: IDSA and AJG assessment may underestimate the potential risk of unfavorable clinical outcome. Further prospective studies on a larger cohort are needed to develop adequate treatment guidelines for CDI in hematology settings.


Asunto(s)
Clostridioides difficile/efectos de los fármacos , Infecciones por Clostridium/tratamiento farmacológico , Neoplasias Hematológicas/complicaciones , Guías de Práctica Clínica como Asunto , Adulto , Infecciones por Clostridium/epidemiología , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Manejo de la Enfermedad , Femenino , Unidades Hospitalarias , Hospitales de Enseñanza , Humanos , Huésped Inmunocomprometido , Masculino , Cumplimiento de la Medicación , Metronidazol/uso terapéutico , Persona de Mediana Edad , Recurrencia , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Vancomicina/uso terapéutico
17.
Med Mal Infect ; 47(2): 92-141, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28279491

RESUMEN

OBJECTIVES: Reducing antibiotic consumption has now become a major public health priority. Reducing treatment duration is one of the means to achieve this objective. Guidelines on the therapeutic management of the most frequent infections recommend ranges of treatment duration in the ratio of one to two. The Recommendation Group of the French Infectious Diseases Society (SPILF) was asked to collect literature data to then recommend the shortest treatment durations possible for various infections. METHODS: Analysis of the literature focused on guidelines published in French and English, supported by a systematic search on PubMed. Articles dating from one year before the guidelines publication to August 31, 2015 were searched on the website. RESULTS: The shortest treatment durations based on the relevant clinical data were suggested for upper and lower respiratory tract infections, central venous catheter-related and uncomplicated primary bacteremia, infective endocarditis, bacterial meningitis, intra-abdominal, urinary tract, upper reproductive tract, bone and joint, skin and soft tissue infections, and febrile neutropenia. Details of analyzed articles were shown in tables. CONCLUSION: This work stresses the need for new well-conducted studies evaluating treatment durations for some common infections. Following the above-mentioned work focusing on existing literature data, the Recommendation Group of the SPILF suggests specific study proposals.


Asunto(s)
Antibacterianos/administración & dosificación , Infecciones Bacterianas/tratamiento farmacológico , Utilización de Medicamentos/estadística & datos numéricos , Humanos , Guías de Práctica Clínica como Asunto , Factores de Tiempo
18.
J Hosp Infect ; 63(1): 70-2, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16542757

RESUMEN

The effect of three stabilized peracetic acid (PAA) preparations (Bioxal M), with or without surfactants, on an Escherichia coli biofilm model was studied. The biofilm was prepared in glass tubes, and was evaluated indirectly using spectrophotometry. The ability of the products to fix or remove the biofilm was determined by their detergent activity (DA). None of the preparations tested fixed the biofilm. The effect of Bioxal M-1 on the biofilm was equivalent to the control (sterile water). Bioxal M-2 and Bioxal M-3 displayed slightly positive DAs. Non-ionic surfactant improved the DA of the products. Regardless of disinfectant activity, PAA agents display different DAs depending on their formulation. This criterion could be used to select the weakest biofilm-fixing agents. Users should therefore be concerned about the efficiency of the cleaning stage of medical devices. When choosing PAA products, non-fixing ability should be considered in addition to antimicrobial activity.


Asunto(s)
Biopelículas/efectos de los fármacos , Desinfectantes/farmacología , Escherichia coli , Ácido Peracético/farmacología , Tensoactivos/farmacología , Colorimetría
19.
Rev Mal Respir ; 23(3 Suppl): 6S11-6S20, 2006 Jun.
Artículo en Francés | MEDLINE | ID: mdl-16820744

RESUMEN

INTRODUCTION: Apart from malignancies and solid organ transplant, chronic lung disease, in particular chronic obstructive pulmonary disease (COPD), is a third important predisposing factor for acute invasive pulmonary aspergillosis. STATE OF THE ART: COPD is present in 2% of patients dying from invasive aspergillosis. This opportunistic infection occurs because of an immunodeficiency linked both to altered local immunity and to systemic factors such as long term steroid treatment and malnutrition. In patients whose sputum and/or endotracheal aspirate specimens contain hyphal forms of filamentous Aspergillus, half will have a clinically significant aspergillus infection. Diagnostic tests include serum galactomannan antigen test, serum antibody titre, thoracic CT scan and bronchoalveolar lavage (BAL). The identification of fungal hyphae in BAL fluid by microscopy and/or on culture is critical for a positive diagnosis. The mortality rate for acute invasive pulmonary aspergillosis in chronic lung diseases reaches almost 100%. Antifungal monotherapy is still recommended as a first line treatment. Combined treatment can be used in refractory aspergillosis as a salvage therapy. The question of maintaining, decreasing or interrupting steroid treatment must be considered. PERSPECTIVES: Prospective studies are needed to evaluate a standardised diagnostic strategy such as exists for patients with haematological disease. Whether this will improve prognosis remains to be seen. CONCLUSION: Acute invasive pulmonary aspergillosis complicating chronic lung disease is not rare. Improved diagnosis procedures and recent therapeutic advances may have a positive impact on patient prognosis.


Asunto(s)
Aspergilosis/etiología , Enfermedades Pulmonares Fúngicas/etiología , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Antifúngicos/uso terapéutico , Aspergilosis/diagnóstico , Causas de Muerte , Humanos , Huésped Inmunocomprometido , Enfermedades Pulmonares Fúngicas/diagnóstico , Infecciones Oportunistas/etiología , Pronóstico , Factores de Riesgo
20.
Med Mal Infect ; 36(2): 63-71, 2006 Feb.
Artículo en Francés | MEDLINE | ID: mdl-16406431

RESUMEN

Surfactant-associated proteins A and D (SP-A and SP-D) are two pulmonary collectins that bind to bacterial, fungal and viral pathogens and have multiples classes of receptors on pneumocyte and macrophage membrane. They are chemoattractant for phagocytes, enhance uptake and killing of bacteria by macrophages and neutrophils. These molecules also act as activation ligand on macrophages and neutrophils to enhance phagocytosis, resulting in an increased bacterial clearance. Depending on activation of cells by stimuli, SP-A and SP-D modulate production of antimicrobial free radicals by phagocytes and secretion of cytokines. In vivo, SP-A deficient mice infected with Pseudomonas aeruginosa (P. aeruginosa) have decreased bacterial clearance and exacerbated inflammatory response in the lungs. Serious alterations in macrophages and increased production of reactive oxygen species were found in non-infected SP-D deficient mice. Patients with cystic fibrosis are frequently colonized by P. aeruginosa. Decreased levels of SP-A and SP-D have been measured in bronchoalveolar lavage fluid of these patients, as well as patients with acute pneumonia but no chronic lung disease. P. aeruginosa secretes various proteases, among them, elastase and protease IV have been found to degrade SP-A and SP-D and abrogate their immune function. However, further investigations are necessary to examine whether these deficiencies facilitate P. aeruginosa infections or stand as consequences.


Asunto(s)
Infecciones por Pseudomonas/fisiopatología , Proteína A Asociada a Surfactante Pulmonar/fisiología , Proteína B Asociada a Surfactante Pulmonar/fisiología , Animales , Proteínas Bacterianas/metabolismo , Citocinas/metabolismo , Humanos , Enfermedades Pulmonares/microbiología , Ratones , Ratones Noqueados , Péptido Hidrolasas/metabolismo , Fagocitos/fisiología , Pseudomonas aeruginosa/enzimología , Proteína A Asociada a Surfactante Pulmonar/deficiencia , Proteína A Asociada a Surfactante Pulmonar/genética , Proteína A Asociada a Surfactante Pulmonar/metabolismo , Proteína B Asociada a Surfactante Pulmonar/genética , Proteína B Asociada a Surfactante Pulmonar/metabolismo , Infecciones del Sistema Respiratorio/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA